Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Moderna, Inc.MRNA · Entity 2025 | Director | May 06, 2026 | May 08, 2026 |
| Tectonic Therapeutic, Inc.TECX · Entity 5328 | Director | April 01, 2026 | April 03, 2026 |
| Tourmaline Bio, Inc.TALS · Entity 15643 | Director | June 13, 2023 | June 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Moderna, Inc.
Report date May 06, 2026 · Filed May 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.79 · Expires 2036-05-06 | Direct | 6,454 |
Reported balance
After 2026-05-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-06 · Grant · Acquired 6,454 · Balance 6,454 F1: This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,185 |
Reported balance
After 2026-05-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-06 · Grant · Acquired 4,185 · Balance 4,185 F2: Restricted stock units convert into common stock on a one-for-one basis. F3: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
F2: Restricted stock units convert into common stock on a one-for-one basis.
F3: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
Tectonic Therapeutic, Inc.
Report date April 01, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.78 · Expires 2036-03-31 | Direct | 20,400 |
Reported balance
After 2026-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 20,400 · Balance 20,400 F1: One Third (1/3) of the shares subject to the option shall vest on April 1, 2027, and the balance shall vest in 24 equal monthly installments thereafter, subject in each case, to the Reporting Person providing continuous service to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One Third (1/3) of the shares subject to the option shall vest on April 1, 2027, and the balance shall vest in 24 equal monthly installments thereafter, subject in each case, to the Reporting Person providing continuous service to the Issuer through each applicable vesting date.
Tourmaline Bio, Inc.
Report date June 13, 2023 · Filed June 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.54 · Expires 2033-06-13 | Direct | 41,000 |
Reported balance
After 2023-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-13 · Grant · Acquired 41,000 · Balance 41,000 F1: The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACCELERON PHARMA INC
Report date November 19, 2021 · Filed November 22, 2021
Section 16 reporting ended · disclosed 2021-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Other · Disposed 6,749 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $27.97 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $30.17 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 7,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $34.14 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-19 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $40.61 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-19 · Disposition to issuer · Disposed 7,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $41.20 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-19 · Disposition to issuer · Disposed 576 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $41.48 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-11-19 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $41.64 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-11-19 · Disposition to issuer · Disposed 7,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $52.99 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-11-19 · Disposition to issuer · Disposed 8,185 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $115.53 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-11-19 · Disposition to issuer · Disposed 3,222 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
ALEXION PHARMACEUTICALS, INC.
Report date July 21, 2021 · Filed July 23, 2021
Section 16 reporting ended · disclosed 2021-07-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-07-21 transaction · row 1
1 source rowRow 1 · 2021-07-21 · Disposition to issuer · Disposed 13,921 · Balance 0 F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,635 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,635 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units.
Prevail Therapeutics Inc.
Report date January 22, 2021 · Filed January 26, 2021
Section 16 reporting ended · disclosed 2021-01-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LLC | 0 |
Reported balance
After 2021-01-22 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-01-22 · Other · Disposed 23,747 · Balance 0 F1: Pursuant to the terms of the Merger Agreement, these shares were tendered and disposed of at the Acceptance Time in exchange for the right to receive (i) $22.50 per share of common stock, net to the seller in cash, without interest (the "Closing Amount"), plus (ii) one contingent value right per share (a "CVR"), which shall represent the right to receive certain consideration based on the achievement of net sales milestones. F2: These shares are held by Jesra Ventures LLC (the "LLC"). The Reporting Person is a manager and a member of the LLC and, as such, may be deemed to share voting and investment power with respect to the shares held by the LLC. The Reporting Person disclaims beneficial ownership of those shares owned by the LLC, except to the extent of his pecuniary interest therein. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.81 | Direct | 0 |
Reported balance
After 2021-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-22 · Disposition to issuer · Disposed 133,447 · Balance 0 F3: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of the Issuer's common stock, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of the Closing Amount over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.26 | Direct | 0 |
Reported balance
After 2021-01-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-01-22 · Disposition to issuer · Disposed 32,000 · Balance 0 F3: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of the Issuer's common stock, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of the Closing Amount over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.98 | Direct | 0 |
Reported balance
After 2021-01-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-01-22 · Disposition to issuer · Disposed 17,000 · Balance 0 F3: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of the Issuer's common stock, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of the Closing Amount over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Merger Agreement, these shares were tendered and disposed of at the Acceptance Time in exchange for the right to receive (i) $22.50 per share of common stock, net to the seller in cash, without interest (the "Closing Amount"), plus (ii) one contingent value right per share (a "CVR"), which shall represent the right to receive certain consideration based on the achievement of net sales milestones.
F2: These shares are held by Jesra Ventures LLC (the "LLC"). The Reporting Person is a manager and a member of the LLC and, as such, may be deemed to share voting and investment power with respect to the shares held by the LLC. The Reporting Person disclaims beneficial ownership of those shares owned by the LLC, except to the extent of his pecuniary interest therein.
F3: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of the Issuer's common stock, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of the Closing Amount over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2026 Filed May 8, 2026 20:59 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 4,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000088 · form4.xml · derivative · entry 2 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,185 Underlying: Common Stock · 4,185 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. F3 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. Read SEC document |
| May 06, 2026 Filed May 8, 2026 20:59 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 6,454 | $0.00 Strike: $48.79 | $0.00 |
DisclosureSEC source: 0001682852-26-000088 · form4.xml · derivative · entry 1 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,454 Underlying: Common Stock · 6,454 shares Expires 2036-05-06 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. Read SEC document |
| April 30, 2026 Filed May 4, 2026 20:48 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 12,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000064 · form4.xml · derivative · entry 2 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,174 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on April 30, 2026. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on April 30, 2026. Read SEC document |
| April 30, 2026 Filed May 4, 2026 20:48 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 12,174 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000064 · form4.xml · nonDerivative · entry 1 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:23 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 20,400 | $0.00 Strike: $30.78 | $0.00 |
DisclosureSEC source: 0001365343-26-000003 · form4-04032026_080427.xml · derivative · entry 1 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,400 Underlying: Common Stock · 20,400 shares Expires 2036-03-31 F1 · derivative.exercise_date: One Third (1/3) of the shares subject to the option shall vest on April 1, 2027, and the balance shall vest in 24 equal monthly installments thereafter, subject in each case, to the Reporting Person providing continuous service to the Issuer through each applicable vesting date. Read SEC document |
| April 30, 2025 Filed May 1, 2025 20:33 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 12,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-012941 · form4.xml · derivative · entry 2 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,174 Underlying: Common Stock · 12,174 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. F3 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. Read SEC document |
| April 30, 2025 Filed May 1, 2025 20:33 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 6,378 | $0.00 Strike: $28.54 | $0.00 |
DisclosureSEC source: 0001127602-25-012941 · form4.xml · derivative · entry 1 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,378 Underlying: Common Stock · 6,378 shares Expires 2035-04-30 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. Read SEC document |
| May 06, 2024 Filed May 7, 2024 21:02 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 7,557 | $0.00 Strike: $122.13 | $0.00 |
DisclosureSEC source: 0001127602-24-014472 · form4.xml · derivative · entry 1 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,557 Underlying: Common Stock · 7,557 shares Expires 2034-05-06 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 23:00 UTC | Tourmaline Bio, Inc. TALS · Entity 15643 | GrantStock Option (Right to Buy) · Derivative | 41,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001209191-23-037188 · doc4.xml · derivative · entry 1 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,000 Underlying: Common Stock · 41,000 shares Expires 2033-06-13 F1 · derivative.exercise_date: The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:14 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 6,134 | $0.00 Strike: $130.14 | $0.00 |
DisclosureSEC source: 0001127602-23-014680 · form4.xml · derivative · entry 1 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,134 Underlying: Common Stock · 6,134 shares Expires 2033-05-03 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of May 3, 2024, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| July 25, 2022 Filed Jul 25, 2022 23:35 UTC | Tourmaline Bio, Inc. TALS · Entity 15643 | OtherCommon Stock | 138,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-026684 · doc4.xml · nonDerivative · entry 7 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By FN TALS LLC Disclosed balance after: 386,932 F7 · kind: Represents the transfer of shares held by the Reporting Person to FN TALS LLC for no consideration. F5 · ownership.nature: These shares are held by a limited liability company of which the Reporting Person serves as the sole member, with sole voting and investment control over the securities held thereby. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 25, 2022 Filed Jul 25, 2022 23:35 UTC | Tourmaline Bio, Inc. TALS · Entity 15643 | OtherCommon Stock | 138,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-026684 · doc4.xml · nonDerivative · entry 6 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F7 · kind: Represents the transfer of shares held by the Reporting Person to FN TALS LLC for no consideration. Read SEC document |
| July 25, 2022 Filed Sep 13, 2022 20:27 UTC Amendment | Tourmaline Bio, Inc. TALS · Entity 15643 | OtherCommon Stock | 138,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030924 · doc4a.xml · nonDerivative · entry 7 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By FN TALS LLC Disclosed balance after: 386,932 F7 · kind: Represents the transfer of shares held by the Reporting Person to FN TALS LLC for no consideration. F5 · ownership.nature: These shares are held by a limited liability company of which the Reporting Person serves as the sole member, with sole voting and investment control over the securities held thereby. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 25, 2022 Filed Sep 13, 2022 20:27 UTC Amendment | Tourmaline Bio, Inc. TALS · Entity 15643 | OtherCommon Stock | 138,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030924 · doc4a.xml · nonDerivative · entry 6 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F7 · kind: Represents the transfer of shares held by the Reporting Person to FN TALS LLC for no consideration. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 23:35 UTC | Tourmaline Bio, Inc. TALS · Entity 15643 | PurchaseCommon Stock | 36,500 | $3.72 | $135,780.00 |
DisclosureSEC source: 0000899243-22-026684 · doc4.xml · nonDerivative · entry 5 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,500 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.595 to $3.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 23:35 UTC | Tourmaline Bio, Inc. TALS · Entity 15643 | OtherCommon Stock | 248,432 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-026684 · doc4.xml · nonDerivative · entry 4 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By FN TALS LLC Disclosed balance after: 248,432 F3 · kind: Represents the transfer of shares held by the Francois Nader 2020 Trust to FN TALS LLC for no consideration. F5 · ownership.nature: These shares are held by a limited liability company of which the Reporting Person serves as the sole member, with sole voting and investment control over the securities held thereby. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 23:35 UTC | Tourmaline Bio, Inc. TALS · Entity 15643 | OtherCommon Stock | 248,432 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-026684 · doc4.xml · nonDerivative · entry 3 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Francois Nader 2020 Trust Disclosed balance after: 87,735 F3 · kind: Represents the transfer of shares held by the Francois Nader 2020 Trust to FN TALS LLC for no consideration. F4 · ownership.nature: These shares are held in a trust for the benefit of the Reporting Person's spouse and child. The Reporting Person's spouse and child are trustees of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 21, 2022 Filed Sep 13, 2022 20:27 UTC Amendment | Tourmaline Bio, Inc. TALS · Entity 15643 | PurchaseCommon Stock | 36,500 | $3.72 | $135,780.00 |
DisclosureSEC source: 0000899243-22-030924 · doc4a.xml · nonDerivative · entry 5 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,500 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.595 to $3.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 21, 2022 Filed Sep 13, 2022 20:27 UTC Amendment | Tourmaline Bio, Inc. TALS · Entity 15643 | OtherCommon Stock | 248,432 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030924 · doc4a.xml · nonDerivative · entry 4 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By FN TALS LLC Disclosed balance after: 248,432 F3 · kind: Represents the transfer of shares held by the Francois Nader 2020 Trust to FN TALS LLC for no consideration. F5 · ownership.nature: These shares are held by a limited liability company of which the Reporting Person serves as the sole member, with sole voting and investment control over the securities held thereby. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 21, 2022 Filed Sep 13, 2022 20:27 UTC Amendment | Tourmaline Bio, Inc. TALS · Entity 15643 | OtherCommon Stock | 248,432 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030924 · doc4a.xml · nonDerivative · entry 3 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Francois Nader 2020 Trust Disclosed balance after: 147,255 F3 · kind: Represents the transfer of shares held by the Francois Nader 2020 Trust to FN TALS LLC for no consideration. F8 · balance_after: This amendment is being filed solely to correct the number of shares reported by the Francois Nader 2020 Trust, which was incorrectly reported due to an administrative error. F4 · ownership.nature: These shares are held in a trust for the benefit of the Reporting Person's spouse and child. The Reporting Person''s spouse and child are trustees of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 20, 2022 Filed Jul 25, 2022 23:35 UTC | Tourmaline Bio, Inc. TALS · Entity 15643 | PurchaseCommon Stock | 52,000 | $3.62 | $188,240.00 |
DisclosureSEC source: 0000899243-22-026684 · doc4.xml · nonDerivative · entry 2 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.51 to $3.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 20, 2022 Filed Sep 13, 2022 20:27 UTC Amendment | Tourmaline Bio, Inc. TALS · Entity 15643 | PurchaseCommon Stock | 52,000 | $3.62 | $188,240.00 |
DisclosureSEC source: 0000899243-22-030924 · doc4a.xml · nonDerivative · entry 2 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.51 to $3.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 19, 2022 Filed Jul 25, 2022 23:35 UTC | Tourmaline Bio, Inc. TALS · Entity 15643 | PurchaseCommon Stock | 50,000 | $3.52 | $176,000.00 |
DisclosureSEC source: 0000899243-22-026684 · doc4.xml · nonDerivative · entry 1 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.38 to $3.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 19, 2022 Filed Sep 13, 2022 20:27 UTC Amendment | Tourmaline Bio, Inc. TALS · Entity 15643 | PurchaseCommon Stock | 50,000 | $3.52 | $176,000.00 |
DisclosureSEC source: 0000899243-22-030924 · doc4a.xml · nonDerivative · entry 1 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.38 to $3.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 22:14 UTC | Tourmaline Bio, Inc. TALS · Entity 15643 | GrantStock Option (Right to Buy) · Derivative | 14,501 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0000899243-22-022249 · doc4.xml · derivative · entry 1 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,501 Underlying: Common Stock · 14,501 shares Expires 2032-06-08 F1 · derivative.exercise_date: The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting. Read SEC document |
| May 10, 2022 Filed May 12, 2022 20:22 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,100 | $0.00 Strike: $18.87 | $0.00 |
DisclosureSEC source: 0001127602-22-014263 · form4.xml · derivative · entry 3 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,620 Underlying: Common Stock · 23,100 shares Expires 2029-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 9, 2022. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| May 10, 2022 Filed May 12, 2022 20:22 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 3,196 | $136.10 | $434,975.60 |
DisclosureSEC source: 0001127602-22-014263 · form4.xml · nonDerivative · entry 2 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,607 F2 · kind: Represents the number of shares sold by the Reporting Person to cover the payment of the exercise price of the option. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $136.10 to $136.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 10, 2022 Filed May 12, 2022 20:22 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 23,100 | $18.87 | $435,897.00 |
DisclosureSEC source: 0001127602-22-014263 · form4.xml · nonDerivative · entry 1 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 9, 2022. Read SEC document |
| April 28, 2022 Filed May 2, 2022 20:40 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 5,415 | $0.00 Strike: $142.52 | $0.00 |
DisclosureSEC source: 0001127602-22-012857 · form4.xml · derivative · entry 3 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,415 Underlying: Common Stock · 5,415 shares Expires not disclosed F3 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F3 · derivative.expiration_date: This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| April 28, 2022 Filed May 2, 2022 20:40 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 703 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-012857 · form4.xml · derivative · entry 2 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 703 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on April 28, 2022. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on April 28, 2022. Read SEC document |
| April 28, 2022 Filed May 2, 2022 20:40 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 703 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-012857 · form4.xml · nonDerivative · entry 1 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 21:05 UTC | Tourmaline Bio, Inc. TALS · Entity 15643 | GiftCommon Stock | 59,520 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-048599 · doc4.xml · nonDerivative · entry 1 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Francois Nader 2020 Trust Disclosed balance after: 336,167 F1 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's spouse and child. The reporting person's spouse and child are trustees of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:06 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 3,222 | Not disclosed Strike: $115.53 | Not disclosed |
DisclosureSEC source: 0001104659-21-142272 · tm2133601-6_4seq1.xml · derivative · entry 10 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,222 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:06 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 8,185 | Not disclosed Strike: $52.99 | Not disclosed |
DisclosureSEC source: 0001104659-21-142272 · tm2133601-6_4seq1.xml · derivative · entry 9 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,185 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:06 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 7,500 | Not disclosed Strike: $41.64 | Not disclosed |
DisclosureSEC source: 0001104659-21-142272 · tm2133601-6_4seq1.xml · derivative · entry 8 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:06 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 20,000 | Not disclosed Strike: $41.48 | Not disclosed |
DisclosureSEC source: 0001104659-21-142272 · tm2133601-6_4seq1.xml · derivative · entry 7 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:06 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 576 | Not disclosed Strike: $41.20 | Not disclosed |
DisclosureSEC source: 0001104659-21-142272 · tm2133601-6_4seq1.xml · derivative · entry 6 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 576 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:06 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 7,500 | Not disclosed Strike: $40.61 | Not disclosed |
DisclosureSEC source: 0001104659-21-142272 · tm2133601-6_4seq1.xml · derivative · entry 5 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:06 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 10,000 | Not disclosed Strike: $34.14 | Not disclosed |
DisclosureSEC source: 0001104659-21-142272 · tm2133601-6_4seq1.xml · derivative · entry 4 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:06 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 7,500 | Not disclosed Strike: $30.17 | Not disclosed |
DisclosureSEC source: 0001104659-21-142272 · tm2133601-6_4seq1.xml · derivative · entry 3 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:06 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 10,000 | Not disclosed Strike: $27.97 | Not disclosed |
DisclosureSEC source: 0001104659-21-142272 · tm2133601-6_4seq1.xml · derivative · entry 2 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:06 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | OtherCommon Stock | 6,749 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-142272 · tm2133601-6_4seq1.xml · nonDerivative · entry 1 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 16:36 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Disposition to issuerCommon Stock, par value $.0001 per share | 13,921 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000065 · wf-form4_162707256224916.xml · nonDerivative · entry 1 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,635 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units. Read SEC document |
| May 20, 2021 Filed May 24, 2021 16:30 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 673 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000043 · wf-form4_162188822137068.xml · nonDerivative · entry 2 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,921 F2 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest as to 25% on a quarterly basis. These Restricted Stock Units were issued in lieu ofthe annual cash retainer that the director was entitled to receive for service as a director. Read SEC document |
| May 20, 2021 Filed May 24, 2021 16:30 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 1,962 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000043 · wf-form4_162188822137068.xml · nonDerivative · entry 1 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,248 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest in their entirety on the first anniversary of the grant date. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:10 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 703 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-014773 · form4.xml · derivative · entry 2 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703 Underlying: Common Stock · 703 shares Expires not disclosed F2 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:10 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 4,081 | $0.00 Strike: $178.68 | $0.00 |
DisclosureSEC source: 0001127602-21-014773 · form4.xml · derivative · entry 1 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,081 Underlying: Common Stock · 4,081 shares Expires 2031-04-28 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 18:26 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 3,222 | $0.00 Strike: $115.53 | $0.00 |
DisclosureSEC source: 0001179110-21-001106 · edgar.xml · derivative · entry 2 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,222 Underlying: Common Stock · 3,222 shares Expires 2031-01-29 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 18:26 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 1,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001106 · edgar.xml · nonDerivative · entry 1 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,749 Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 17:12 UTC | Prevail Therapeutics Inc. PRVL · Entity 11821 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $16.98 | $0.00 |
DisclosureSEC source: 0001209191-21-005429 · doc4.xml · derivative · entry 4 Nader Francois · CIK 0001365343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of the Issuer's common stock, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of the Closing Amount over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F3 · derivative.expiration_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of the Issuer's common stock, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of the Closing Amount over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.